Zydus gets USFDA nod for blood pressure injection

Published On 2022-07-22 11:35 GMT   |   Update On 2022-07-22 11:35 GMT
Advertisement

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), has announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Norepinephrine Bitartrate Injection USP,4 mg/4 mL (1 mg/mL) Single-Dose Vial.

Norepinephrine Bitartrate is indicated for restoration of blood pressure in adult patients with acute hypotensive state.

For more details, check out the full story on the link below:

Zydus Lifesciences Bags USFDA Okay For Norepinephrine Bitartrate Injection


Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News